Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Patrick Y. Wen, MD
- Target Recruit Count
- 26
- Registration Number
- NCT01339039
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Gene Therapy for Fanconi Anemia
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01331018
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01318317
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT01301963
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
- Conditions
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 46
- Registration Number
- NCT01288573
- Locations
- 🇳🇱
Investigational Site Number 71, Rotterdam, Netherlands
🇵🇱Investigational Site Number 85, Krakow, Poland
🇭🇺Investigational Site Number 83, Budapest, Hungary
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Mitchell Horwitz, MD
- Target Recruit Count
- 41
- Registration Number
- NCT01280955
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
- Conditions
- Interventions
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 113
- Registration Number
- NCT01236144
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
Mozobil for Autologous Stem Cell Mobilization
- Conditions
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01164345
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel-Hashomer, Israel
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01160354
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT01158118
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.